MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ofid/ofaf119

Медицинская библиотека · Open forum infectious diseases · 2025

Dolutegravir-based Antiretroviral Therapy in People With HIV With Solid Organ Transplantation: A Single-arm Pilot Clinical Trial (DTG-SOT).

Miro Jose M, Malano-Barletta Daniela, Berrocal Leire, Manzardo Christian, Castelli Anna, Brunet Mercè, Roman Octavi, Ambrosioni Juan, Cofán Frederic, Gonzalez Angela, Ruiz Pablo, Crespo Gonzalo, Forner Alejandro, Ángeles Castel M, Laguno Montse, Tuset Montse, de Lazzari Elisa, Rimola Antoni, Moreno Asunción, SOT in HIV-infected patients Working Group Investigators

Клиническое исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

This study assessed the pharmacokinetic interactions between dolutegravir (DTG)-based antiretroviral therapy (ART) and immunosuppressants in solid organ transplantation (SOT) recipients with HIV and ART safety.

METHODS

A phase IV, single-center, open-label, single-arm clinical trial (DTG-SOT, NCT03360682) including adult SOT recipients with HIV conducted between 2017 and 2019. People with HIV with plasma viral load <50 copies/mL during ≥12 months and receiving stable raltegravir-based ART during ≥6 months were switched to tenofovir disoproxil fumarate/emtricitabine or lamivudine/abacavir + DTG and followed up for 48 weeks. Immunosuppressant pharmacokinetic parameters were compared before and 2 weeks after ART switch (primary outcome). Efficacy and safety were analyzed at 48 weeks by intention-to-treat analysis.

RESULTS

Nineteen consecutive participants (median, 57 years; interquartile range, 51-60), mostly liver recipients (63.2%), received DTG/lamivudine/abacavir (63.2%) and DTG + emtricitabine/tenofovir disoproxil fumarate (36.8%). Pharmacokinetic parameters changed, albeit not significantly, before and after ART, for mycophenolic acid (maximum [Cmax] +63%, trough [Cmin] +53%, area under the curve [AUC] +16%; n = 7) and cyclosporine A (Cmax -64%, Cmin +14%, AUC -47%; n = 2), with smaller changes for tacrolimus (Cmax +14%, Cmin -29%, AUC -9%; n = 7). No participants experienced acute rejection or virological failure and CD4+ cell counts and percentages remained unchanged during follow-up. Three (15.8%) discontinued treatment because of adverse events. Estimated glomerular filtration rate decreased (P = 0.0015) and creatinine increased (P = 0.0001) slightly.

CONCLUSIONS

DTG-based ART lacked clinically significant drug-drug interactions with tacrolimus and mycophenolic acid. Switching to DTG-based ART was effective in people with HIV SOT recipients. More studies are needed to evaluate DTG safety in this setting.

Для цитирования: Miro Jose M, Malano-Barletta Daniela, Berrocal Leire, Manzardo Christian, Castelli Anna, Brunet Mercè, Roman Octavi, Ambrosioni Juan, Cofán Frederic, Gonzalez Angela, Ruiz Pablo, Crespo Gonzalo, Forner Alejandro, Ángeles Castel M, Laguno Montse, Tuset Montse, de Lazzari Elisa, Rimola Antoni, Moreno Asunción, SOT in HIV-infected patients Working Group Investigators. Dolutegravir-based Antiretroviral Therapy in People With HIV With Solid Organ Transplantation: A Single-arm Pilot Clinical Trial (DTG-SOT).. Open forum infectious diseases. 2025. DOI: 10.1093/ofid/ofaf119.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.